Download PDF
Dtsch Med Wochenschr 2015; 140(19): 1431-1434
DOI: 10.1055/s-0041-105627
Dossier
Krebsfrüherkennung
© Georg Thieme Verlag KG Stuttgart · New York

Das Gallengangskarzinom: Von neuen Erkenntnissen der Epidemiologie zur Früherkennung

New insights into epidemiology may promote screening in Cholangiocarcinoma
Jörg Gerhard Albert
1   Medizinische Klinik 1, Universitätsklinikum Frankfurt
,
Oliver Waidmann
1   Medizinische Klinik 1, Universitätsklinikum Frankfurt
,
Tania Mara Welzel
1   Medizinische Klinik 1, Universitätsklinikum Frankfurt
› Author Affiliations
Further Information

Publication History

Publication Date:
24 September 2015 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Das Cholangiokarzinom (CCA) ist eine vergleichsweise seltene maligne Erkrankung des hepatobiliären Systems. Aufgrund der geringen Inzidenz der Erkrankung ist eine generelle Vorsorgeuntersuchung der gesamten Bevölkerung weder aus Ressourcen- noch aus Evidenzgründen zu empfehlen. In Westeuropa und in Deutschland stellen chronische Leberkrankungen wie die Leberzirrhose ursprünglicher Ätiologie sowie die PSC Hauptrisikofaktoren für die Entstehung des CCA dar. Diese Patientengruppen weisen das höchste Risiko auf, an einem CCA zu erkranken und sollten daher ähnlich der „HCC surveillance“ beim Hepatozellulären Karzinom engmaschig kontrolliert werden. Neue endoskopische Techniken wie die Cholangioskopie können insbesondere bei der Abklärung von unklaren Strikturen der extrahepatischen Gallenwege bei PSC-Patienten die Diagnostik unterstützen.

Eine große Herausforderung stellt die Zunahme der Insulinresistenz, des metabolischen Syndroms und damit einhergehend der massive Anstieg der Fallzahl an Patienten mit nicht-alkoholischer Fettleber (NAFLD) dar. Da Patienten mit Diabetes mellitus ein erhöhtes Risiko für die Erkrankung an einem CCA haben, wird es eine große Herausforderung darstellen unter dieser großen Anzahl an Patienten diejenigen zu identifizieren, die das höchste Risiko für die Erkrankung an einem CCA aufweisen, um sie dann Früherkennungsmaßnahmen zuzuführen.

Abstract

Cholangiocarcinoma is non-curable in many cases at establishing the diagnosis. New insights into epidemiology may promote screening of cholangiocarcinoma in a combination of risk scores, but today PSC is the only risk factor with an established screening recommendation.

Schlüsselwörter

Cholangiokarzinom - Epidemiologie - Primäre sklerosierende Cholangitis - Endoskopisch-retrograde cholangiopancreatographie ERCP - Metabolisches Syndrom

Keywords

cholangiocarcinoma - epidemiology - primary sclerosing cholangitis - endoscopic retrograde cholangiopancreatography (ERCP) - metabolic syndrome
 

  • Literatur

  • 1 Bergquist A, von Seth E. Epidemiology of cholangiocarcinoma. Best practice and research in Clinical gastroenterology 2015; 29: 221-232
    CrossrefPubMedGoogle Scholar
  • 2 Ulrich F, Albert J, Zangos S. Diagnostik und Therapie des cholangiozellulären Karzinoms. Der Onkologe 2013; 19: 589-600
    CrossrefPubMedGoogle Scholar
  • 3 DeOliveira ML, Cunningham SC, Cameron JL et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007; 245: 755-762
    CrossrefPubMedGoogle Scholar
  • 4 Shin H, Oh J, Masuyer E et al. Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer science 2010; 101: 579-585
    CrossrefPubMedGoogle Scholar
  • 5 Welzel TM, Graubard BI, El-Serag HB et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol 2007; 5: 1221-1228
    CrossrefPubMedGoogle Scholar
  • 6 Li Y, Wang H, Li D et al. Occult hepatitis B virus infection in Chinese cryptogenic intrahepatic cholangiocarcinoma patient population. J Clin Gastroenterol 2014; 48: 878-882
    PubMedGoogle Scholar
  • 7 Bergquist A, Ekbom A, Olsson R et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002; 36: 321-327
    CrossrefPubMedGoogle Scholar
  • 8 Lee BS, Cha BH, Park E, Roh J. Risk factors for perihilar cholangiocarcinoma: a hospital-based case-control study. Liver int 2015; 35: 1048-1053
    CrossrefPubMedGoogle Scholar
  • 9 Donato F, Gelatti U, Tagger A et al. Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy. Cancer Causes Control 2001; 12: 959-964
    CrossrefPubMedGoogle Scholar
  • 10 Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 2005; 128: 620-626
    CrossrefPubMedGoogle Scholar
  • 11 Welzel TM, Mellemkjaer L, Gloria G et al. Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study. Int J Cancer 2007; 120: 638-641
    CrossrefPubMedGoogle Scholar
  • 12 Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol 2012; 57: 69-76
    CrossrefPubMedGoogle Scholar
  • 13 Zhou Y, Zhao Y, Li B et al. Hepatitis viruses infection and risk of intrahepatic cholangiocarcinoma: evidence from a meta-analysis. BMC Cancer 2012; 12: 289
    CrossrefPubMedGoogle Scholar
  • 14 Welzel TM, Graubard BI, Zeuzem S et al. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology 2011; 54: 463-471
    CrossrefPubMedGoogle Scholar
  • 15 Khan SA, Emadossadaty S, Ladep NG et al. Rising trends in cholangiocarcinoma: is the ICD classification system misleading us?. J Hepatol 2012; 56: 848-854
    CrossrefPubMedGoogle Scholar
  • 16 Ramchandani M, Reddy DN, Gupta R et al. Role of single-operator peroral cholangioscopy in the diagnosis of indeterminate biliary lesions: a single-center, prospective study. Gastrointest Endosc 2011; 74: 511-519
    CrossrefPubMedGoogle Scholar
  • 17 Ezoe Y, Muto M, Uedo N et al. Magnifying narrowband imaging is more accurate than conventional white-light imaging in diagnosis of gastric mucosal cancer. Gastroenterology 2011; 141: 2017-2025.e3
    CrossrefPubMedGoogle Scholar
  • 18 Monga A, Ramchandani M, Reddy DN. Per-oral cholangioscopy. J Interv Gastroenterol 2011; 1: 70-77
    CrossrefPubMedGoogle Scholar
  • 19 Charatcharoenwitthaya P, Enders FB, Halling KC, Lindor KD. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 2008; 48: 1106-1117
    CrossrefPubMedGoogle Scholar
  • 20 Levy C, Lymp J, Angulo P et al. The value of serum CA 19–9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci 2005; 50: 1734-1740
    CrossrefPubMedGoogle Scholar
  • 21 Trikudanathan G, Navaneethan U, Njei B, Vargo JJ, Parsi MA. Diagnostic yield of bile duct brushings for cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis. Gastrointest Endosc 2014; 79: 783-789
    CrossrefPubMedGoogle Scholar
  • 22 Navaneethan U, Njei B, Lourdusamy V et al. Comparative effectiveness of biliary brush cytology and intraductal biopsy for detection of malignant biliary strictures: a systematic review and meta-analysis. Gastrointest Endosc 2015; 81: 168-176
    CrossrefPubMedGoogle Scholar
  • 23 Boberg KM, Jebsen P, Clausen OP et al. Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 2006; 45: 568-574
    CrossrefPubMedGoogle Scholar
  • 24 Tischendorf JJW, Kruger M, Trautwein C et al. Cholangioscopic characterization of dominant bile duct stenoses in patients with primary sclerosing cholangitis. Endoscopy 2006; 38: 665-669
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Furmanczyk PS, Grieco VS, Agoff SN. Biliary brush cytology and the detection of cholangiocarcinoma in primary sclerosing cholangitis: evaluation of specific cytomorphologic features and CA19–9 levels. Am J Clin Pathol 2005; 124: 355-360
    CrossrefPubMedGoogle Scholar
  • 26 Siqueira E, Schoen RE, Silverman W et al. Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. Gastrointest Endosc 2002; 56: 40-47
    CrossrefPubMedGoogle Scholar
  • 27 Ponsioen CY, Vrouenraets SM, van Milligen de Wit AW et al. Value of brush cytology for dominant strictures in primary sclerosing cholangitis. Endoscopy 1999; 31: 305-309
    Article in Thieme ConnectPubMedGoogle Scholar
  • 28 Glasbrenner B, Ardan M, Boeck W et al. Prospective evaluation of brush cytology of biliary strictures during endoscopic retrograde cholangiopancreatography. Endoscopy 1999; 31: 712-717
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Arnelo U, von Seth E, Bergquist A. Prospective evaluation of the clinical utility of single-operator peroral cholangioscopy in patients with primary sclerosing cholangitis. Endoscopy 2015; 47: 696-702
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Farnik H, Weigt J, Malfertheiner P et al. A multicenter study on the role of direct retrograde cholangioscopy in patients with inconclusive endoscopic retrograde cholangiography. Endoscopy 2014; 46: 16-21
    Article in Thieme ConnectPubMedGoogle Scholar
  • 31 Chen YK, Parsi MA, Binmoeller KF et al. Single-operator cholangioscopy in patients requiring evaluation of bile duct disease or therapy of biliary stones (with videos). Gastrointest Endosc 2011; 74: 805-814
    CrossrefPubMedGoogle Scholar
  • 32 Sethi A, Chen YK, Austin GL et al. ERCP with cholangiopancreatoscopy may be associated with higher rates of complications than ERCP alone: a single-center experience. Gastrointest Endosc 2011; 73: 251-256
    CrossrefPubMedGoogle Scholar
  • 33 Razumilava N, Gores GJ, Lindor KD. Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology 2011; 54: 1842-1852
    CrossrefPubMedGoogle Scholar
  • 34 Albert MB, Steinberg WM, Henry JP. Elevated serum levels of tumor marker CA19–9 in acute cholangitis. Dig Dis Sci 1988; 33: 1223-1225
    CrossrefPubMedGoogle Scholar